Conflict of Interest: Dr. Rapoport is on the speakers bureau of Allergan, Nautilus Neurosciences, and Zogenix. He is a consultant to Allergan, Impax, MAP, Nautilus Neurosciences, NuPathe, Winston, and Zogenix.
Acute Treatment of Migraine: Established and Emerging Therapies
Article first published online: 2 OCT 2012
© 2012 American Headache Society
Headache: The Journal of Head and Face Pain
Special Issue: Proceedings of the Headache Cooperative of New England 2012 Meeting, Stowe, Vermont
Volume 52, Issue Supplement s2, pages 60–64, October 2012
How to Cite
Rapoport, A. M. (2012), Acute Treatment of Migraine: Established and Emerging Therapies. Headache: The Journal of Head and Face Pain, 52: 60–64. doi: 10.1111/j.1526-4610.2012.02240.x
- Issue published online: 2 OCT 2012
- Article first published online: 2 OCT 2012
- Accepted for publication June 1, 2012.
- migraine treatment;
- acute therapy of migraine;
- non steroidal anti-inflammatory drug;
- migraine pipeline
Migraine is a chronic, episodic, often disabling, neurological condition that affects more than 12% of the US population, 3 times more in women than men. It has widespread effects on cerebral function and appears to be inherited. There are many types of therapy including behavioral, complementary, acute pharmacologic care, preventive pharmacologic care, and physical techniques. General treatment principles include lifestyle changes and using rapidly acting acute care medications alone or in combination early in the migraine attack. Migraine-specific medications such as triptans and non steroidal anti-inflammatory drugs should be used when possible. There are several promising medications and devices in the migraine pipeline.